Ambrohexal solution for oral administration and inhalation 7.5 mg/ml 100 ml bottle No. 1

Compound

One Ambrohexal tablet contains ambroxol hydrochloride (active ingredient) - 0.03 g + excipients ( calcium hydrogen phosphate, corn starch, magnesium stearate, lactose monohydrate, sodium carboxymethyl starch, colloidal silicon dioxide ).
Capsules (extended release) contain active ingredient - 0.075 g + excipients ( eudragide RL30D, triethyl citrate, titanium dioxide, eudrahydride RS30D, red iron oxide, MCC, magnesium stearate ).

Ambrohexal syrup. For 5 ml of syrup, the active substance is 0.015 mg + excipients ( benzoic acid, raspberry essence, citric acid monohydrate, sorbitol solution, polyvidone, sodium cyclamate, sodium metabesulfite, water, sodium hydroxide, glycerol ).

A solution for inhalation and oral administration (one milliliter) contains the active substance - 7.5 mg + excipients ( citric acid, methyl parahydroxybenzoate, sodium disulfite, sodium hydroxide, purified water ).

Buy Ambrohexal solution for internal use 7.5 mg/ml 50 ml in pharmacies

AmbroHexal Buy AmbroHexal in pharmacies DOSAGE FORMS solution for oral administration and inhalation 7.5 mg/ml oral solution 7.5 mg/ml

MANUFACTURERS Hexal Pharma GmbH (Germany) Salutas Pharma GmbH (Germany)

GROUP Mucolytic agents

COMPOSITION Active substance: Ambroxol.

INTERNATIONAL NON-PROPENTED NAME Ambroxol

SYNONYMS Ambrobene, Ambroxol, Ambroxol-Verte, Ambroxol-Vial, Ambroxol-Vramed, Ambroxol-Hemofarm, Ambroxol hydrochloride, Ambrosan, Ambrosol, Bronchoxol, Bronchorus, Lazolvan, Medox, Neo-Bronchol, Suprima-kof, Flavamed, Halixol

PHARMACOLOGICAL ACTION Mucolytic, expectorant. Stimulates the formation of low-viscosity tracheobronchial secretions and increases the secretion of glycoproteins (mucokinetic effect). Stimulates the motor activity of the cilia of the ciliated epithelium and improves mucociliary transport; increases the synthesis and secretion of surfactant and blocks its breakdown. Biotransformed in the liver. In the form of water-soluble metabolites, most are excreted in the urine.

INDICATIONS FOR USE Bronchitis, pneumonia and bronchial asthma with difficulty in sputum discharge, bronchiectasis, respiratory distress syndrome in premature infants and newborns.

CONTRAINDICATIONS Hypersensitivity, peptic ulcer of the stomach and duodenum, pregnancy (first trimester), breastfeeding.

SIDE EFFECTS Weakness, headache, gastralgia, nausea, vomiting, diarrhea, exanthema; with rapid intravenous administration - intense headaches, weakness.

INTERACTION Increases the penetration of amoxicillin, cefuroxime, erythromycin and doxycycline into the bronchial secretions. The injection solution is pharmaceutically incompatible (in one syringe) with solutions of drugs whose pH exceeds 6.3.

METHOD OF APPLICATION AND DOSAGE orally for adults - 4 ml 3 times a day for 2-3 days, then - 4 ml 2 times or 2 ml 3 times a day; children under 2 years old - 1 ml 2 times a day, 2-5 years old - 1 ml 3 times a day, 5-12 years old - 2 ml 2-3 times a day.

OVERDOSE No information available.

SPECIAL INSTRUCTIONS Please note that 5 ml of syrup contains sorbitol and saccharin in an amount corresponding to 0.18 XE (may be important for patients with diabetes). It should not be combined with other antitussives that make it difficult to remove sputum.

STORAGE CONDITIONS Store at room temperature, protected from light.

Release form

• Round and flat tablets (white, with rounded edges) with a score line on one side. Packages of 20, 30, 50 and 100 pieces.
• White gelatin capsules with white or pinkish powder inside. Packages of 10, 20, 50 or 100 pieces.
• Transparent, slightly yellowish viscous syrup. Available in 100 or 250 ml bottles, including a measuring spoon.
• Ambrohexal solution for inhalation and oral administration is transparent, colorless. In bottles with a dispenser and a measuring cup of 50 and 100 mg.

Ambroxol solution

Release form

The solution for oral administration and inhalation is colorless or brown, transparent, with a weak characteristic odor.

Compound

Active ingredient : ambroxol hydrochloride (7.5 mg/ml).

Excipients : sodium chloride, sodium hydrogen phosphate dihydrate, citric acid monohydrate, benzalkonium chloride, purified water.

Pharmacological group

Mucolytic and expectorant drug. Secretolytics and stimulants of motor function of the respiratory tract.

Action

Mucolytic agent with expectorant action. Ambroxol increases the secretion of the glands of the respiratory tract, stimulates the activity of the villi of the respiratory tract, and enhances the formation of surfactant in the lungs. Ambroxol is a metabolite of bromhexine.

Ambroxol - description of the substance

After oral administration, the effect occurs within 30 minutes and lasts for 6-12 hours (depending on the dose taken).

Indications

Acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum:

• chronic bronchitis with broncho-obstructive syndrome;
• pneumonia;
• bronchial asthma;
• COPD;
• bronchiectasis.

Contraindications and restrictions

• Peptic ulcer of the stomach and duodenum;
• convulsive syndrome of various etiologies;
• I trimester of pregnancy;
• hypersensitivity to ambroxol.

Carefully

• in the II and III trimesters of pregnancy;
• during lactation (breastfeeding);
• in patients with renal and/or liver failure.

Application and dosage

1 ml of solution for oral administration and inhalation contains 7.5 mg of ambroxol.

Inside

Take orally after meals, adding to water, juice, tea or milk using a measuring cup or spoon.

• , adults and adolescents are prescribed 4 ml of solution 3 times a day (90 mg/day). In the following days - 4 ml 2 times / day (60 mg / day).
• Children under 2 years of age - 1 ml of solution 2 times a day (15 mg/day);
• from 2 to 6 years - 1 ml of solution 3 times a day (22.5 mg/day);
• from 6 to 12 years - 2 ml of solution 2-3 times a day (30-45 mg/day).

The duration of treatment is determined individually depending on the course of the disease. It is not recommended to take ambroxol for more than 4-5 days without a doctor's prescription. The mucolytic effect of the drug occurs when taking large amounts of liquid. Therefore, drinking plenty of fluids is recommended during treatment.

In the form of inhalations

Use any modern equipment (except steam inhalers). Before inhalation, the drug should be mixed with a 0.9% sodium chloride solution (for optimal air humidification it can be diluted in a ratio of 1:1) and heated to body temperature. Inhalations should be carried out in normal breathing mode so as not to provoke coughing shocks.

• Adults and children over 6 years of age inhale 2-3 ml of solution 1-2 times a day (15-45 mg/day).
• Children from 2 to 6 years old - 2 ml of solution 1-2 times a day (15-30 mg/day).
• Children under 2 years old - 1 ml of solution 1-2 times a day (7.5-15 mg/day).

special instructions

Patients on a hyposodium diet should keep in mind that 1 ml of ambroxol solution contains 10 mg of sodium. The maximum daily dose for adults and children over 12 years of age contains 120 mg of sodium.

Storage

Store out of the reach of children at room temperature no higher than 25°C. Shelf life: from 3 years.

Production

• JSC "PFC Renewal"»;
• Atoll LLC (Ozon LLC);
• LLC "Tula Pharmaceutical Factory";
• JSC "Marbiopharm";
• JSC "VERTEX" and others.

Package

• Bottle (from 10 to 100 ml) in a cardboard pack. Complete with or without a measuring cup or measuring spoon.
• Dropper tubes (4 ml) 10 or 15 pcs. in a cardboard pack. Complete with or without solvent.

Recipe

Available without a prescription.

Pharmacodynamics and pharmacokinetics

The active ingredient, ambroxol, belongs to the group of benzylamines . Restores the normal balance between the serous and mucous components of the bronchial secretion , by increasing the secretion of the mucous membrane and directly affects the active cells in the bronchial glands. The substance stimulates the activity of special villi of the respiratory tract , thereby facilitating its movement through the bronchi. Ambroxol hydrochloride also has the property of reducing the viscosity of sputum by depolymerizing mucopolysaccharides . The amount of bronchial secretion does not increase, stimulation of centers causing increased cough does not occur.

In a period of time from half an hour to three hours, when taking tablets orally, the drug reaches its maximum concentration in the lungs. About 90% of the substance binds to blood proteins . Most of the drug is excreted by the kidneys 6-11 hours after administration as a glucuronide (or unchanged), the rest is metabolized in the liver tissue.

Ambrohexal solution for oral administration and inhalation 7.5 mg/ml 100 ml bottle No. 1

Trade name of the drug: AMBROGEXAL International nonproprietary name (INN): Ambroxol Dosage form: syrup.

Composition: 1 ml of syrup contains: Active substance: ambroxol hydrochloride 3 mg/ml Other ingredients: benzoic acid, sodium metabisulfite, citric acid monohydrate, sodium hydroxide, polyvidone, sorbitol solution 70%, glycerin 85%, sodium cyclamate, raspberry flavor, purified water.

Description Transparent or almost transparent, colorless or slightly yellowish liquid (similar to syrup), without foreign particles. Pharmacotherapeutic group: Medicines used for coughs and colds. Mucolytic agents. ATX code: [К.05СВ06]

Pharmacological properties Pharmacodynamics It has a secretomotor (improving sputum transport) and secretolytic effect (reducing the viscosity of sputum), facilitates expectoration; stimulates the serous cells of the glands of the bronchial mucosa, increases the content of mucous secretion and the release of surfactant in the alveoli and bronchi; normalizes the disturbed ratio of serous and mucous components of sputum. By activating hydrolyzing enzymes and enhancing the release of lysosomes from Clark cells, it reduces the viscosity of sputum. Increases the motor activity of the cilia of the ciliated epithelium, increases the mucociliary transport of sputum. After oral administration, the effect occurs within 30 minutes. and continues for 6-12 hours. Pharmacokinetics Absorption is high, time to reach maximum concentration is 1-3 hours after oral administration, binding to blood plasma proteins is 80-90%. The drug is metabolized in the liver to inactive metabolites (dibromanthranilic acid and glucuronic conjugates). The half-life from plasma (T1/2) is from 7 to 12 hours. The total plasma half-life of ambroxol and its metabolites is approximately 22 hours. 90% of ambroxol is excreted by the kidneys in the form of metabolites, 10% unchanged. Due to its high protein binding and large volume of distribution, as well as slow redistribution from tissues to blood, significant elimination of ambroxol by dialysis or forced diuresis is not expected. Ambroxol clearance decreases by 20 - 40% in severe hepatopathy. In cases of severe renal dysfunction, the half-life of ambroxol metabolites increases. Ambroxol penetrates the blood-brain barrier, the placental barrier, and is excreted in breast milk.

Indications for use Acute and chronic diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, chronic obstructive pulmonary disease, pneumonia, bronchial asthma with difficulty in sputum discharge, bronchiectasis.

Contraindications Hypersensitivity to ambroxol or other components of the drug; children under 2 years of age.

Directions for use and dosage Adults: 2-3 days, 3 times a day, 2 scoops (equivalent to 90 mg of ambroxol hydrochloride per day), and then 2 times a day, 2 scoops (equivalent to 60 mg of ambroxol hydrochloride per day). In severe cases of the disease, the dose is not reduced throughout the entire course of treatment. The maximum dose is 2 times a day, 4 scoops (equivalent to 120 mg of ambroxol hydrochloride per day). Children aged 6 to 12 years: prescribed 2-3 times a day, 1 measuring spoon (equivalent to 30-45 mg of ambroxol hydrochloride per day). Children aged 2 to 5 years: prescribed 3 times a day, 1A measuring spoon (equivalent to 22.5 mg of ambroxol hydrochloride per day). During treatment, it is necessary to drink plenty of fluids (juices, tea, water) to enhance the mucolytic effect of the drug. The duration of therapy depends on the severity of the disease and is determined by the attending physician. Without a doctor's recommendation, you should not take AmbroHEXAL for more than 4-5 days.

Side effects Like all medicines, Ambrohexal can cause side effects, although not everyone gets them. The assessment of side effects is based on the frequency of their occurrence: very common: more than 1 in 10 patients common: 1 - 10 patients in 100 uncommon: 1 - 10 patients in 1,000 rare: 1 - 10 patients in 10,000 very rare : less than 1 in 10,000 patients not established: based on available data, cannot be established. Disorders of the immune system, skin and subcutaneous tissues Uncommon: hypersensitivity reactions (rash, urticaria and other reactions of the skin and mucous membranes, angioedema, shortness of breath, itching), fever Very rare: anaphylactic reactions, including anaphylactic shock Disorders of the nervous system systems Common: taste disturbance (change in taste) Digestive system disorders Common: nausea, diarrhea Uncommon: vomiting, dyspepsia and abdominal pain Rare: heartburn Very rare: constipation, hypersalivation Respiratory, chest and mediastinal disorders Common: numbness of the mouth and pharynx Uncommon: dry mouth Very rare: rhinorrhea, dry airways Frequency unknown: dry throat Renal and urinary tract disorders Very rare: dysuria If you notice any adverse reactions, including those not mentioned in this leaflet , please tell your doctor about this.

Special instructions and precautions for use There have been very rare reports of severe skin lesions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, which were associated in time with the use of expectorants such as ambroxol hydrochloride. In most cases, such reactions were associated with the severity of the patient's underlying disease and/or concomitant therapy. Additionally, in the early stages of Stevens-Johnson syndrome or toxic epidermal necrolysis, patients may initially experience flu-like symptoms, such as fever, body aches, runny nose, cough and sore throat. It is possible that due to confusion by these nonspecific flu-like symptoms, symptomatic treatment was started with cold and cough medications. In this regard, if signs of a reaction appear on the skin or mucous membrane, you should immediately consult a doctor and, as a precaution, stop treatment with ambroxol hydrochloride. If you have impaired renal function or severe hepatopathy, you should take ambroxol only after consulting your doctor. As with any drug with hepatic metabolism followed by renal excretion, accumulation of ambroxol metabolites should be expected in severe renal failure. In patients with impaired bronchial motility and copious bronchial secretions (as, for example, in the rare syndrome of primary ciliary dyskinesia), Ambrohexal should be used with caution due to the risk of difficulty with the discharge of large amounts of sputum and blockage of the bronchi. Patients with rare congenital fructose intolerance should not take this medicine.

Instructions for diabetics: 1 measuring spoon (5 ml of syrup) contains 1.75 g of sorbitol (less than 0.15 XE).

Interaction with other drugs The use of ambroxol hydrochloride with antitussive drugs leads to complications in sputum discharge while reducing cough, so this combination should not be used. The use of ambroxol hydrochloride with antibiotics (amoxicillin, cefuroxime, erythromycin and doxycycline) increases the concentration of antibiotics in sputum and bronchial secretions.

Use during pregnancy and breastfeeding The drug is not recommended for use during the first trimester of pregnancy. If it is necessary to use ambroxol in the II-III trimesters of pregnancy, the potential benefit for the mother should be assessed with the possible risk to the fetus. Ambroxol hydrochloride is excreted into breast milk, and therefore its use is not recommended during breastfeeding.

Overdose Overdose caused by ambroxol is not accompanied by serious toxic effects. Symptoms: possible transient anxiety, diarrhea. With a significant overdose, hypersalivation, vomiting, and arterial hypotension are possible. Treatment: emergency measures such as inducing vomiting and gastric lavage are not indicated; they are used only in case of significant overdose in the first 1-2 hours. If necessary, symptomatic therapy is recommended.

Effect on the ability to drive a car and operate machinery There are no prerequisites for the drug to influence the ability to drive vehicles or operate machinery. No studies have been conducted on this effect.

Release form Syrup 3 mg/ml. 100 ml in dark glass bottles. A bottle with a measuring spoon in a cardboard box with instructions for use.

Storage conditions: Protected from light at a temperature not exceeding 25C. Keep out of the reach of children!

Shelf life: 3 years. Store an opened bottle for no more than 1 year! Do not use the drug after the expiration date.

Dispensed from pharmacies Without a prescription. Manufacturer

Side effects

• nausea, epigastric pain , dry mouth , diarrhea ;
• dryness in the nasal cavity or, on the contrary, excessive secretion;
• allergic reactions, incl. on the skin;
• general weakness , dysuria .

metabisulfite may develop ( diarrhea, shock, loss of consciousness, nausea, asthmatic attacks ).

Instructions for use of Ambrohexal (Method and dosage)

When taking tablets, the daily dose for an adult (over 12 years of age) in the first three days is 90 mg per day, divided into 3 doses. Further, the dosage can be reduced to 60 mg. Children (from 6 years old) are prescribed 30-45 mg per day.

For extended-release capsules, the main condition is to maintain the integrity of the shell when taken. As a rule, 75 mg of the drug (1 tablet) is prescribed after meals, once a day. Not recommended for use by children under 12 years of age.

The syrup is prescribed for adults (from 12 years old) 30 mg (2 scoops) 3 times a day for the first few days. Next - the same amount 2 times a day. The maximum daily dose is 60 mg.

Children from 5 years old - 1 spoon 3 times a day, from 2 to 5 - half a spoon, up to 2 years old - half a spoon 2 times a day.

According to the instructions for Ambrohexal for inhalation , adults are prescribed 80 drops 3 times a day in the first days, then 80 drops 2 times a day. Children under 12 years old - 40 drops 3 times a day, up to 5 years old - 20 drops 3 times a day, up to 2 years old - 20 drops 2 times a day.

The solution for oral administration and inhalation can be diluted in tea, juice, milk or water.

How to dilute drops for inhalation?

The medicine should be diluted with 0.9% saline. solution , in equal proportions approximately 50% to 50%. The prepared solution should be heated to 40-50 degrees. Children should inhale the vapor for 2-3 minutes, adults – up to five minutes.

For adults (over 5 years old), inhalations are made twice a day, diluted with 50 drops.

For children under 5 years old, dilute 40 drops, inhalation – 2 times a day.

You should not use the drug in any form for more than five days, without supervision or consultation with a doctor.

Ambrohexal syrup

Release form

Syrup . Transparent, almost colorless or light yellow solution.

Compound

Active ingredient : ambroxol hydrochloride (3 mg/ml or 6 mg/ml).

Excipients:

For syrup 3 mg/ml - benzoic acid; sodium metabisulfite; citric acid monohydrate; sodium hydroxide; povidone; sorbitol (70% solution); glycerol 75%; sodium cyclamate; raspberry flavor; purified water.

For syrup 6 mg/ml - benzoic acid; glycerol 85%; hyaetellosis; sorbitol (70% solution); apricot flavoring; propylene glycol; levomenthol; purified water.

Pharmacological group

Secretolytics and stimulants of motor function of the respiratory tract.

Action

Mucolytic agent with expectorant action. Ambroxol increases the secretion of the glands of the respiratory tract, stimulates the activity of the villi of the respiratory tract, and enhances the formation of surfactant in the lungs. Ambroxol is a metabolite of bromhexine.

Ambroxol: description of the substance

Indications

Diseases of the respiratory tract with the formation of viscous sputum:

• acute and chronic bronchitis;
• pneumonia;
• COPD;
• bronchial asthma with difficulty in sputum discharge;
• bronchiectasis.

Contraindications and restrictions

• Hypersensitivity to ambroxol or other components of the drug;
• hereditary fructose intolerance;
• pregnancy (II and III trimester).

Carefully

• Kidney failure and liver failure;
• peptic ulcer of the stomach and duodenum;
• II and III trimesters of pregnancy.

Application and dosage

Inside.

Raspberry syrup 3 mg/ml

1 scoop of syrup contains 15 mg of ambroxol hydrochloride.

• Adults and children over 12 years of age - 2 scoops (5 ml) 3 times a day (60-90 mg ambroxol hydrochloride) for the first 2-3 days, then 2 scoops (5 ml) 2 times a day.
• Children aged 6 to 12 years - 1 measuring spoon (2.5 ml) 2-3 times a day;
• from 2 to 5 years - 1/2 measuring spoon (1.25 ml) 3 times a day;
• under 2 years - 1/2 measuring spoon (1.25 ml) 2 times a day.

Apricot syrup 6 mg/ml

1 scoop of syrup contains 30 mg of ambroxol hydrochloride.

• Adults and children over 12 years old - 1 measuring spoon (5 ml) 3 times a day for the first 2-3 days, then 1 measuring spoon (5 ml) 2 times a day.
• Children aged 6 to 12 years - 1/2 measuring spoon (2.5 ml) 2-3 times a day;
• from 2 to 5 years - 1/4 measuring spoon (1.25 ml) 3 times a day;
• under 2 years - 1/4 measuring spoon (1.25 ml) 2 times a day.

For children under 2 years of age, Ambrohexal is prescribed only under the supervision of a physician.

Storage

In a place protected from light, at a temperature not exceeding 25 °C. Shelf life: 2 years.

Production

• Sandoz (Slovenia);
• Lichtenheldt GmbH Pharmaceuticals Factory (Germany);
• Salutas Pharma GmbH (Germany).

Package

A dark glass bottle of 100 ml or 250 ml with a measuring spoon (scoop) in a cardboard box.

Recipe

Available without a prescription.

Interaction

Can be combined with drugs prescribed for bronchial asthma .

antibiotics ( erythromycin, amoxicillin, cefuroxime with caution ; this will increase their concentration in the body.

It is not recommended to combine with codeine and other antitussives .

Ambrohexal syrup 3mg/ml 100ml No.1

Name

Ambrohexal syrup 3 mg/ml in vial. 100ml per pack. No. 1

Description

Transparent or almost transparent, colorless or slightly yellowish liquid (similar to syrup), without foreign particles.

Main active ingredient

Ambroxol

Release form

Syrup

Dosage

3mg/ml

pharmachologic effect

Pharmacodynamics

It has a secretomotor and secretolytic effect (i.e., it improves the removal of sputum and reduces its viscosity), facilitates expectoration, stimulates the serous cells of the glands of the bronchial mucosa, increases the content of mucous secretions and the release of surfactant (surfactant) in the alveoli and bronchi; normalizes the disturbed ratio of serous and mucous components of sputum. By activating hydrolyzing enzymes and enhancing the release of lysosomes from Clara cells, it reduces the viscosity of sputum. Increases the motor activity of the cilia of the ciliated epithelium, increases the mucociliary transport of sputum. After oral administration, the effect occurs within 30 minutes and lasts for 6-12 hours.

Pharmacokinetics

Absorption is high, time to reach maximum concentration after oral administration is 1-3 hours, duration of action is 6-12 hours. Absolute bioavailability is 79%. Plasma protein binding is approximately 90%. About 30% of the administered oral dose is eliminated as a result of first-pass metabolism in the liver (“first-pass effect”). Ambroxol hydrochloride is metabolized mainly in the liver through glucuronidation, the formation of dibromanthranilic acid (about 10% of the dose), as well as other minor metabolites. Studies on human liver microsomes have shown that CYP3A4 is involved in the metabolism of ambroxol hydrochloride to dibromanthranilic acid. After three days of oral administration, about 6% of the dose is excreted in free form, about 26% of the dose is found in the urine in the form of conjugates. Total clearance ranges from 660 ml/min, renal clearance accounts for approximately 8% of the total clearance. Due to its high protein binding and large volume of distribution, as well as slow redistribution from tissues to blood, significant elimination of ambroxol by dialysis or forced diuresis is not expected. Ambroxol clearance decreases by 20-40% in severe liver damage. In severe renal impairment, the half-life of ambroxol metabolites increases. Ambroxol penetrates the blood-brain and placental barriers and is excreted in breast milk. Pharmacokinetics of special groups of patients In patients with impaired liver function, the excretion of ambroxol is reduced, resulting in plasma levels increasing by 1.3-2 times. Due to the wide therapeutic range of ambroxol hydrochloride, no dose adjustment is required. Age and gender of patients Age and gender do not have a clinically significant effect on the pharmacokinetics of ambroxol hydrochloride, and therefore no dose adjustment is required.

Indications for use

Acute and chronic diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, chronic obstructive pulmonary disease, pneumonia, bronchial asthma with difficulty in sputum discharge, bronchiectasis.

Directions for use and doses

Take orally, regardless of meals. Adults and adolescents over 12 years of age: 2-3 days, 3 times a day, 30 mg of ambroxol hydrochloride (10 ml or 2 measuring spoons of syrup), and then 2 times a day, 30 mg of ambroxol hydrochloride (10 ml or 2 measuring spoons of syrup ). In severe cases of the disease, the dose is not reduced throughout the entire course of taking the drug. The maximum dose is 60 mg of ambroxol hydrochloride (20 ml or 4 scoops of syrup) 2 times a day. For adolescents aged 12 years and older and adults taking high doses, ambroxol cough syrup 6 mg/ml or ambroxol 30 mg tablets are recommended. Children aged 6 to 12 years: prescribed 2-3 times a day, 15 mg of ambroxol hydrochloride (5 ml or 1 scoop). Children aged 2 to 5 years: prescribed 7.5 mg of ambroxol hydrochloride (2.5 ml or ½ measuring spoon) 3 times a day. If the condition improves, after 2-3 days the dosage regimen can be changed to 2 times a day (every 12 hours). Elderly patients with normal renal function are recommended to take the usual dosage. Patients with hepatic or renal impairment: Caution is required. If you miss a regular dose, do not exceed a single dose of the drug at a subsequent dose. To enhance the secretolytic effect of the drug, drink plenty of fluids (juices, tea, water). The duration of use depends on the severity of the disease. Do not take the drug for more than 4-5 days without consulting a doctor. If the condition does not improve or worsens after 5 days of taking the drug, consult your doctor.

Use during pregnancy and lactation

The drug is not recommended for use during the first trimester of pregnancy. If it is necessary to use ambroxol in the II-III trimesters of pregnancy, the potential benefit to the mother and the possible risk to the fetus should be assessed. Ambroxol hydrochloride passes into breast milk, and therefore its use is not recommended during breastfeeding.

Precautionary measures

Severe skin reactions, such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalized exanthematous pustulosis, have been reported in association with ambroxol hydrochloride. If symptoms or signs of a progressive skin rash appear (sometimes accompanied by the formation of blisters or changes in the mucous membranes), stop taking AmbroHEXAL® immediately and consult a doctor. In most cases, such reactions were associated with the severity of the patient's underlying disease and (or) the use of concomitant medications. Additionally, in the early stages of Stevens-Johnson syndrome or toxic epidermal necrolysis, patients may initially present with flu-like symptoms, such as fever, body aches, runny nose, cough, and sore throat. It is possible that due to confusion by these nonspecific flu-like symptoms, symptomatic treatment was started with cold and cough medications. If you have impaired renal function or severe liver disease, AmbroHEXAL® should be taken only after consulting a doctor. As with any drug with hepatic metabolism followed by renal excretion, accumulation of ambroxol metabolites should be expected in severe renal failure. In patients with impaired bronchial motility and copious bronchial secretions (as, for example, in the rare syndrome of primary ciliary dyskinesia), AmbroHEXAL® should be used with caution due to the risk of difficulty with the discharge of large amounts of sputum and blockage of the bronchi. Patients with rare congenital fructose intolerance should not take this drug. The drug contains sorbitol, which may have a mild laxative effect. The drug contains metabisulfite, which in rare cases can cause severe hypersensitivity reactions and bronchospasm. Instructions for patients with diabetes: 1 scoop (5 ml of syrup) contains 1.75 g of sorbitol (less than 0.15 bread units).

Interaction with other drugs

The use of ambroxol hydrochloride with antitussive drugs leads to complications in sputum discharge while reducing cough, so this combination should not be used. The use of ambroxol hydrochloride with antibiotics (amoxicillin, cefuroxime, erythromycin and doxycycline) increases the concentration of antibiotics in sputum and bronchial secretions.

Contraindications

Hypersensitivity to ambroxol hydrochloride or excipients of the drug; children under 2 years of age.

Compound

1 ml of syrup contains: Active substance: ambroxol hydrochloride 3 mg. Excipients: benzoic acid (E 210), sodium metabisulfite (E 223), citric acid monohydrate, sodium hydroxide, polyvidone, sorbitol solution 70% (E 420), glycerin 85% (E 422), sodium cyclamate, raspberry flavor, water purified.

Overdose

Overdose caused by ambroxol is not accompanied by serious toxic effects. Symptoms: possible transient anxiety, diarrhea. With a significant overdose, hypersalivation, vomiting, and arterial hypotension are possible. Treatment: emergency measures such as inducing vomiting and gastric lavage are not indicated; they are used only in case of significant overdose in the first 1-2 hours. If necessary, symptomatic therapy is recommended.

Side effect

Like all medicines, AmbroHEXAL® can cause side effects, although not everyone gets them. The assessment of side effects is based on the frequency of their occurrence: very common: more than 1 in 10 patients common: 1-10 patients in 100 uncommon: 1-10 patients in 1,000 rare: 1-10 patients in 10,000 very rare : less than 1 in 10,000 patients, frequency unknown: cannot be determined from available data. Immune system disorders Rare: hypersensitivity reactions. Not known: anaphylactic reactions, including anaphylactic shock, angioedema and pruritus. Digestive system disorders Common: nausea, oral hypoesthesia. Uncommon: vomiting, diarrhea, dyspepsia and abdominal pain, dry mouth. Very rare: constipation, drooling. Frequency unknown: dry throat. Skin and subcutaneous tissue disorders Rare: rash, urticaria. Not known: severe cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis and acute generalized exanthematous pustulosis). Nervous system disorders Common: taste disorder (change in taste). Respiratory, thoracic and mediastinal disorders Common: pharyngeal hypoesthesia. Very rare: rhinorrhea. Renal and urinary tract disorders Very rare: dysuria. Other Rarely: drug fever. If you notice any side effects, including those not mentioned in these instructions, please notify your doctor.

Storage conditions

Keep out of the reach of children! Store in a place protected from light at a temperature not exceeding 25 °C.

Buy Ambrohexal syrup 3 mg/ml in bottle. 100ml per pack. No. 1 in pharmacy

Price for Ambrohexal syrup 3 mg/ml in vial. 100ml per pack. No. 1

Instructions for use for Ambrohexal syrup 3 mg/ml in vial. 100ml per pack. No. 1

Analogs

Level 4 ATX code matches:
Mukolik

Abrol

Ambrosan

Bronchorus

ACC 100

ACC 200

ACC Long

ACC

Mukolwan

Lazolvan

Bromhexine 8

Bromhexine 8 Berlin-Chemie

Bromhexine

Bronchobos

Carbocisteine

Erdomed

Pulmozyme

Pectolvan C

Halixol

Ambrobene

Abrol, ambroxol, ambronorm, bronchoval, flavamed for cough, ambrosal, lasolvan, lazongin, ambrobene, ambrolitin, ambrospray, ambrochem, bronchoval, lazolex, mucosol, medox, pulmibrom, mucotablin, medovent.

Lazolvan or Ambrohexal - which is better?

Both drugs contain the same active ingredient ambroxol. The effectiveness of the impact is approximately the same. The cost of Ambrohexal is lower than that of its analog Lazolvan .

Reviews about Ambrohexal

Reviews for Ambrohexal tablets are good. Helps against severe dry cough, has virtually no side effects. Many consider the advantage of the drug to be its low cost and high availability. The syrup has approximately the same popularity and characteristics, and has a pleasant sweet taste. As a rule, the cough goes away within a week after starting treatment with the drug.

Reviews of inhalation with the solution are positive. Convenient release form, high efficiency and speed of recovery are the main advantages of the drug. Many people use inhalations with Ambrohexal and saline solution for young children and are happy with the results. The disadvantage is the unpleasant taste of this form of the drug.

Price (where to buy)

The cost of Ambrohexal tablets is about 84 rubles for 20 pieces.

Long-acting capsules will cost 120 rubles for 10 pieces.

A bottle of liquid for inhalation costs about 92 rubles per 50 ml.

The syrup costs approximately 103 rubles per 100 ml.

• Online pharmacies in RussiaRussia

ZdravCity

• Ambrohexal tablets 30 mg 20 pcs. Salutas Pharma GmbH
  RUB 109 order